As interest builds in the field of bispecific antibodies, one-year-old China-based Epimab Biotherapeutics Inc. is preparing for a series A financing and just announced its first licensing deal for the company's flagship technology platform, FIT-Ig or Fabs-In-Tandem.
Following the money, the company expects to hire 20 employees and move in July from a virtual two-man operation to an office in the Zhangjiang Hi-Tech Park in Shanghai's Pudong district.
Chairman and CEO Chengbin Wu and COO/CBO Stephan Lensky met with about 20 potential partners and presented FIT-Ig to a standing-room-only audience at the 8th annual Chinabio Partnering Forum held in Suzhou, China, in May.
"The technology allows you to basically combine any type of two antibodies into a bispecific," Lensky told BioWorld Today. "Since the possibilities are extremely large, we can actually work in various directions, but we can never make all of these